Tiger Brokers

Pfizer Gets Full FDA Approval for Braftovi Combination for Colon Cancer Treatment

MT Newswires Live
Yesterday

Pfizer (PFE) received full approval from the US Food and Drug Administration for its drug Braftovi in combination with Erbitux and fluorouracil-based chemotherapy for the treatment of adults with BRAF V600E-mutated metastatic colorectal cancer.

The conversion from accelerated approval was based on "significant benefit in outcomes" for both progression-free survival and overall survival in a Phase 3 study, Pfizer said Tuesday in a statement.

The Braftovi combination is under regulatory review in Europe and has been approved in several other countries, Pfizer said.

Eli Lilly (LLY) manufactures and commercializes Erbitux in North America.

Pfizer shares rose 0.3% in Tuesday trading, and Lilly fell 1.4%.

Price: 27.15, Change: +0.09, Percent Change: +0.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10